CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Triomics nabs $22M to bring oncology-specific AI to cancer centers

From TechCrunch

By Marina Temkin

May 27, 2026

Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics, a startup building an AI-powered platform to help oncologists and administrative staff automate data-heavy tasks like clinical trial matching and appointment prep, has raised $22 million in Series B funding.

The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator, and others.

The good news is that oncology breakthroughs are keeping patients alive longer. That welcome trend, however, is creating dense, multi-year medical records that take healthcare staff a long time to review and decipher.

A typical medical chart includes physician progress notes, imaging and pathology reports, and even scans of faxes. “We have seen medical records [with] thousands of pages of information,” Triomics co-founder Sarim Khan told TechCrunch.

Founded in 2021, the startup raised a $15 million Series A in mid-2024. Initially focused on helping doctors identify the most suitable clinical trials for their patients, Triomics expanded its platform as LLM capabilities grew. Over the last couple of years, Triomics added verifiable patient summaries to its platform as part of a broader visit-preparation workflow, surfacing key information directly within the tools clinicians already use, without requiring them to switch applications.

By reducing appointment prep time, these summaries give oncologists more time with their patients. The efficiency gain matters beyond individual appointments: In oncology, where patient histories are unusually complex and staff burnout is a persistent problem, tools that reduce administrative load have an outsized impact.

Triomics is also used to automate the tedious task of submitting tumor reports to government registries, a legal mandate for cancer centers.

While generic AI agents excel at basic summaries, prominent institutions like Memorial Sloan Kettering (MSK) and Yale Cancer Center use Triomics because its models are trained specifically on oncology data, Khan explained.

Triomics’ most direct competition comes from AI medical scribes like Abridge and Microsoft’s Nuance — tools that use AI to listen to and document patient-doctor conversations — when it comes to summarizing patient charts.

Despite the fierce competition, Triomics is growing fast. According to Khan, the startup expanded its enterprise customer base fourfold over the past year, driving a tenfold increase in annualized recurring revenue.

Pictured left to right: Sarim Khan, Triomics co-founder and CEO, and Hrituraj Singh, Triomics co-founder and CTO.

View original article on techcrunch.com

Most Recent

ServiceNow AI Control Tower: Selling a penthouse while building the frame

ServiceNow Inc. is making one of the more consequential and visible bets in enterprise AI. The company says AI Control Tower can discover and govern any agent, work across models and clouds, track cost and value, and shut down behavior that violates policy. That sales pitch plays directly to Service

Oct 17, 2026

What to expect during Dell’s ‘Cyber Resilience’ event: Join theCUBE Oct. 27

Data protection and cyber recovery are foundational to enterprise AI. See how Dell is rethinking resilience at the theCUBE's Oct. 27 summit.

Oct 16, 2026

RapidCanvas raises $29M to develop custom AI applications for enterprises

Software development startup RapidCanvas Inc. today announced that it has raised $29 million in funding. Vertex Ventures SEA & India led the Series B round with contributions from Hitachi Ventures, Accel, Peak XV Partners, Valley Capital Partners and Titanium Ventures. The deal follows a $16 million

Oct 16, 2026

Tressfecta wants to make hair braiding a less arduous task for hairstylists

Tressfecta builds products for textured hair. Its first project is a tool called Plait Pilot that helps braiders with the initial process of separating hair from packs before braiding begins.

Oct 16, 2026

Similar Posts

Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion

L to R: Thyme Care Co-founder and Chief Medical Officer Bobby Green,; Thyme Companies Executive Chairman Robin Shah; Thyme Care CEO Brad DiephuisCourtesy: Thyme CareDespite recent advancements in oncology, the branch of medicine focused on the study, prevention, diagnosis and treatment of cancer, it

Sep 3, 2026

Grove cuts clinical trial enrollment time with AI

Tran Le was an engineering student at Stanford University when she tried to enroll in a clinical trial for her chronic condition. Although she identified several promising trials, she found the sign-up process daunting — she had to have extensive email exchanges with clinical sites and complete lengthy 20-page forms. All that paperwork was so cumbersome, Le saw an opportunity to use generative AI to reduce the time it takes to get started with a trial from weeks to minutes. Last year, she teame

Jan 8, 2025

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

When it comes to data, perhaps no sector has as much of it and in as many distinct silos as the healthcare industry. Hundreds of millions of patient records reside within various electronic health records (EHRs) maintained by vendors like Epic, Cerner and Athena. Insurance companies hold extensive data sets on coverage, reimbursement rates, and patient demographics. Pharmacies and laboratories contribute further data points on medication usage and diagnostic results. Over the last decade or so

Jan 9, 2025